Add onc brain to your Home Screen: tap Share, then Add to Home Screen.
ROAM/EORTC-1308: adjuvant IMRT 60 Gy/30 fx after GTR of WHO grade 2 atypical meningioma, DFS HR 0.51 (0.27–0.97), 5-yr DFS 79.9% vs 64.3% vs observation.
The only study today is CNS: randomised adjuvant RT vs observation after complete resection of atypical meningioma, median f/u 64 mo. The ITT DFS benefit favours RT, but the trial closed short of its 46-event target. As-treated HR 0.54 (0.28–1.04) crossed 1, and recurrence was read locally in an unmasked trial.
read the full digest →Studies · 134
- ROAM/EORTC-1308Adjuvant IMRT 60 Gy/30 fx vs observation after complete resection of WHO grade 2 atypical meningioma: DFS HR 0.51 (0.27–0.97); 5-yr DFS 79.9% vs 64.3%.
- BIG 3-07/TROG 07.01Tumour bed boost after WBI in resected non-low-risk DCIS: 5-yr freedom from LR 97.1% vs 92.7%, HR 0.47 (0.31-0.72), p<0.001.
- TRT in Prostate Cancer Survivors (Bhasin RCT)Sexual activity +0.91 daily events vs placebo (95% CI 0.56-1.26, P<.001) with 12wk testosterone; zero biochemical recurrences in low-grade post-RP hypogonadal men.
- ASTRO Clinical Practice Guideline: RT for Bladder CancerTMT recommended (strong, high QoE) as alternative to RC for select cT2-4aN0M0 MIBC; bladder-alone 5500 cGy/20 fx or 6400-6480 cGy/32-36 fx.
- Gamma Knife vs LINAC-based radiosurgery for vestibular schwannoma (retrospective review)Local control 98.8%; no difference in new vertigo, gait disturbance or facial palsy with GKRS (n=36) vs LINAC (n=49) SRS for vestibular schwannoma.
- SWOG S1827/MAVERICKRandomized phase III, LS or ES SCLC: PCI 25 Gy/10 fx + MRI vs MRI surveillance alone; no CFFS or OS results in source tweets.
- TORPEdO18% vs 7% 12-mo G-tube dependence/≥20% weight loss (p=0.079), UW-QoL 78.3 vs 77.1 (p=0.56): IMPT not superior to IMRT, locally advanced oropharyngeal SCC.
- PROTEUS5-yr BCR-FS 44%, MFS 71%, CSS 92% at 60-mo median f/u in a real-world high-risk prostate cancer benchmark cohort.
- MARCAP ConsortiumIPD meta-analysis, 10,853 pts: ADT added to RT improved MFS HR 0.83 and OS HR 0.86; dose escalation improved bRFS only.
- STAR-TREC12-mo TME-free survival 78.5% vs 60.6% (HR 1.90) favouring LCCRT over SCRT for organ preservation in mrT1-T3bN0 rectal cancer ≤40 mm.
- Focal Ablation vs IMRT Toxicity (SEER-Medicare)GI toxicity favored focal therapy at 24mo (11.0% vs 21.5%, OR 0.45) but GU toxicity favored IMRT (41.7% vs 29.3%, OR 1.69).
- NRG-GU0053yr DFS 88.6% SBRT vs 92.1% MH-IMRT, superiority rejected (adjusted HR 1.40, 0.91-2.13); bowel and GU toxicity favored SBRT.